1. Harrela, M., Koistinen, H., Kaprio, J., Lehtovirta, M., Tuomilehto, J., Eriksson, J., Toivanen, L., Koskenvuo, M., Leinonen, P., Koistinen, R. and Seppala, M. (1996) Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J. Clin. Invest., 98, 2612–2615.
2. Burtrum, D., Zhu, Z., Lu, D., Anderson, D.M., Prewett, M., Pereira, D.S., Bassi, R., Abdullah, R., Hooper, A.T., Koo, H. et al. (2003) A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res., 63, 8912–8921.
3. Sachdev, D., Li, S.L., Hartell, J.S., Fujita-Yamaguchi, Y., Miller, J.S. and Yee, D. (2003) A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res., 63, 627–635.
4. Yu, H. and Rohan, T. (2000) Role of the insulin-like growth factor family in cancer development and progression. J. Natl Cancer Inst., 92, 1472–1489.
5. Hadsell, D.L., Murphy, K.L., Bonnette, S.G., Reece, N., Laucirica, R. and Rosen, J.M. (2000) Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis. Oncogene, 19, 889–898.